Correlation of Released HMGB1 Levels With the Degree of Islet Damage in Mice and Humans and With the Outcomes of Islet Transplantation in Mice

Establishing reliable islet potency assay is a critical and unmet issue for clinical islet transplantation. Recently. we reported that islets contained high levels of high mobility group box 1 (HMGB1) and damaged islets released HMGB I in a mouse model. In this study, we hypothesized that the amount of released HMGB I could reflect the degree of islet damage, and could predict the outcome of islet transplantation. Four groups of damaged mouse islets and three groups of damaged human islets were generated by hypoxic conditions. These islets were assessed by in vivo (transplantation) and in vitro (released HMGB I levels, released C-peptide levels, PI staining, TUNEL staining, ATP/DNA, and glucose-stimulated insulin release test) assays. In addition, the ability of each assay to distinguish between noncured (n = 13) and cured (n = 7) mice was assessed. The curative rates of STZ-diabetic mice after receiving control, hypoxia-3h, hypoxia-6h, and hypoxia-24h mouse islets were 100%, 40%, 0%, and 0%, respectively. Only amounts of released HMGB I and ratio of PI staining significant increased according to the degree of damages in both human and mouse islets. In terms of predictability of curing diabetic mice, amounts of released HMGB1 showed the best sensitivity (100%), specificity (100%), positive (100%), and negative predictive values (100%) among all the assays. The amount of released HMGB I reflected the degree of islet damage and correlated with the outcome of islet transplantation in mice. Hence, released HMGB 1 levels from islets should be a useful marker to evaluate the potency of isolated islets.